Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines

British Journal of Cancer

Volumn 74, Issue 11, 1996, Pages 1719-1729

  Lehne, G ^a   De Angelis, P ^a   Clausen, O P F ^a   Rugstad, H E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anthracycline; Flow cytometry; Hepatoma; Human cell line; Multidrug resistance; P glycoprotein

Indexed keywords

ACLARUBICIN; ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; GLYCOPROTEIN P; VALSPODAR; VERAPAMIL;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; DRUG TRANSPORT; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0029801099     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.621     Document Type: Article

References (65)

1. ADEN DP, FOGEL A, PLOTKIN S, DAMJANOV I AND KNOWLES BB. (1979). Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature, 282, 615-616.
2. BACHUR NR, STEELE M, MERIWETHER WD AND HILDEBRAND RC. (1976). Cellular pharmacodynamics of several anthracycline antibiotics. J. Med. Chem., 19, 651-654.
3. BAEKELANDT M, KRISTENSEN G, HOLM R, NESLAND J AND TROPÉ C. (1994). P-gp expression as a possible marker for response to cisplatinum/epirubicin as a first line treatment in advanced ovarian cancer. Anti-Cancer Drugs, 5 (suppl. 1), 59.
4. BATES DA, FUNG H AND MACKILLOP WJ. (1985). Adriamycin uptake, intracellular binding and cytotoxicity in Chinese hamster ovary cells. Cancer Lett., 28, 213-221.
5. BATES SE, ZAHN Z, DICKSTEIN B, LEE JS, SCALA S, FOJO AT, PAULL K AND WILSON W. (1994). Reversal of multidrug resistance. J. Hematother., 3, 219-223.
6. BATIST G, TULPULE A, SINHA BK, KATKI AG, MYERS CE AND COWAN KH. (1986). Overexpression of a novel anionic glutathione transferase in multidrug-resistant breast cancer cells. J. Biol. Chem., 261, 15544-15549.
7. BEPPU T, OHARA C, YAMAGUCHI Y, ICHIKARA T, YAMANAKA T, KATAFUCHI S, IKEI S, MORI K, FUKUSHIMA S, NAKANO M AND OGAWA M. (1991). A new approach to chemoembolization for unresectable carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. Cancer, 68, 2555-2560.
8. BHALLA K, HINDENBURG A, TAUB RN AND GRANT S. (1985). Isolation and characterization of an anthracycline-resistnat human leukemic cell line. Cancer Res., 45, 3657-3662.
9. BOESCH D, GAVERIAUX C, JACHEZ B, POURTIER-MANZANEDO A, BOLLINGER P AND LOOR F. (1991). In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 51, 4226-4233.
10. BROCK I, HIPFNER DR, NIELSEN BS, JENSEN PB, DEELEY RG, COLE SP AND SEHESTED M. (1995). Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res., 55, 459-462.
11. CAMPOS L, GUYOTAT D, ARCHIMBAUD E, CALMARD-ORIOL P, TSURUO T, TRONCY J, TREILLE D AND FIERE D. (1992). Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoid leukemia cells at diagnosis. Blood, 79, 473-476.
12. CHAN HS, THORNER PS, HADDAD G AND LING V. (1990). Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol., 8, 689-704.
13. CHAN HS, HADDAD G, THORNER PS, DEBOER G, LIN YP, ONDRUSEK N AND LING V. (1991). P-glycoprotein expression as a predictor of the outcome of therapy for neuroblasloma. N. Engl. J Med., 325, 1608-1614.
14. COLE SP, CHANDA ER, DICKE FP, GERLACH JH AND MIRSKI SEL. (1991). Non-P-glycoprotein-mediated resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase H. Cancer Res., 51, 3345-3352.
15. COLE SP, BHARDWAJ G, GERLACH JH, MACKIE JE, GRANT CE, ALMQUIST KC, STEWARD AJ, KURZ EU, DUNCAN AM AND DEELEY RG. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650-1654.
16. COLEY HM, TWENTYMAN PR AND WORKMAN P. (1989). Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclcosporin A. Biochem. Pharmacol., 38, 4467-4471.
17. COLEY HM, TWENTYMAN PR AND WORKMAN P. (1990). 9-alkyl morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur. J. Cancer, 26, 665-667.
18. COLEY HM, TWENTYMAN PR AND WORKMAN P. (1993). The efflux of anthracyclines in multidrug-resistant cell lines. Biochem. Pharmacol., 46, 1317-1326.
19. CORNWELL MM, PASTAN I AND GOTTESMAN MM. (1987). Certain calcium channel blockers bind specifically to multidrug resistant KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J. Biol. Chem., 262, 2166-2170.
20. DANTCHEV D, SLIOUSSARTCHOUK V, PAINTRAND M, HAYAT M, BOURUT M AND MATHÉ G. (1979). Electron microscopic studies of the heart and light macroscopic studies of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD-32 and aclacinomycin. Cancer Treat. Rep., 63, 875-888.
21. EGORIN MJ, HILDEBRAND RC, CIMINO EF AND BACHUR NR. (1974). Cytofluorescence localization of adriamycin and daunorubicin. Cancer Res., 34, 2243-2245.
22. EGORIN MJ, VAN ECHO D, FOX BM, WHITACRE M AND BACHUR NR. (1982). Plasma kinetics of aclacinomycin A and its major metabolites in man. Cancer Chemother. Pharmacol., 8, 41-46.
23. EIJDEMS EW, DE HAAS M, TIMMERMANN AJ, VAN DER SCHANS GP, KAMST E, DE NOOIJ, ASTALDI RICOTTI CG, BORST P AND BAAS F. (1995). Reduced topoisomerase II activity in multidrug-resistant human non-small-cell lung cancer cell lines. Br. J. Cancer, 71, 40-47.
24. ENDICOTT JA AND LING V. (1989). The biochemistry of P-glycoprotein mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171.
25. FALKSON G, MACINTYRE JM AND MOERTEL CG. (1984). Primary liver cancer. Cancer. 54, 977-980.
26. FOXWELL BMJ, MACKIE A, LING V AND RYFFEL B. (1989). Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol. Pharm., 36, 543-546.
27. FRICHE E, JENSEN PB AND NISSEN NI. (1992). Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother. Pharmacol., 30, 235-237.
28. FRISHMAN W, KIRSTEN E, KLEIN M, PINE M, JOHNSON SM, HILLIS LD, PACKER M AND KATES R. (1982). Clinical relevance of verapamil plasma levels in stable angina pectoris. Am. J. Cardiol., 50, 1180-1184.
29. HALL KS, ENDRESEN L, HUITFELDT HS AND RUGSTAD HE. (1991). Induction of in vitro resistance to 4′-epidoxorubicin and cis-dichlorodiamineplatinum in hepatoma cells. Anticancer Res., 11, 817-824.
30. HAMADA H AND TSURUOT. (1986). Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl Acad. Sci. USA, 83, 7785-7789.
31. HAMANN SR, TODD GD AND MCALLISTER SR JR. (1983). The pharmacology of verapamil V. Tissue distribution of verapamil and norverapamil in rat and dog. Pharmacology, 27, 1-8.
32. HORI S, SHIRAI M, HIRANO S, OKI T, INUIT T, TSUKAGOSHI S, ISHIZUKA M, TAKEUCHI T AND UMEZAWA H. (1977). Antitumour activity of new anthracycline antibiotics, Aclacinomycin-A and its analogs and their toxicity. Gann, 68, 685-690.
33. ICHIKARA T, SAKAMOTO K, MORI K AND AKAGI M. (1989). Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polyactic acid microspheres containing aclarubicin hydrochloride. Cancer Res., 49, 4357-4362.
34. ITSUBO M, ISHIKAWA T, TODA G AND TANAKA M. (1994). Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer, 73, 298-303.
35. JENSEN PB, SØRENSEN BS, SEHESTED M, DERMANT EJ, KJELDSEN E, FRICHE E AND HANSEN HH. (1993). Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem. Pharmacol., 45, 2025-2035.
36. JULIANO RL AND LING V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455, 152-162.
37. KNOWLES BB, HOWE CC AND ADEN DP. (1980). Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science, 209, 497-499.
38. LEHNE G, DEANGELIS P, CLAUSEN OPF, HALL KS, HUITFELDT HS AND RUGSTAD HE. (1994). Pharmacokinetics and cytotoxicity of Epirubicin (EPI) in drug resistant human hepatoma cells (HB8065). Int. J. Oncol., 4, 1229-1235.
39. LEHNE G, DEANGELIS P, CLAUSEN OPF, EGELAND T, TSUROU T AND RUGSTAD HE. (1995). Diversity of externally and internally binding anti-P-glycoprotein antibodies in flow cytometric analysis of multidrug resistant cell lines. Cytometry, 20, 228-237.
40. LICHT T, PASTAN I, GOTTESMAN M AND HERRMANN F. (1994). P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann. Hematol., 69, 159-171.
41. MACHOVER D, GASIABURN J, DELGADO M, GOLDSCHMIDT E, HULHOVEN R, MISSET JL, DE VASSAL F, TAPIERO H, RIBAUD P, SCHWARZENBERG L AND MATHÉ G. (1984). Phase I-II study of aclarubicin for treatment of acute myeloid leukemia. Cancer Treat. Rep., 68, 881-886.
42. MARIE J-P, ZITTOUN R AND SIKIC BI. (1991). Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood, 78, 586-592.
43. MARTINI A, MORO E, PACCIARINI MA, TAMASSIA V, NATALE N AND PIAZZA E. (1984). Cross-over study pharmacokinetics and haemotological toxicity of 4′-epi-doxorubicin in cancer patients. Int. J. Clin. Pharm. Res., 4, 231-238.
44. MERIWETHER WD AND BACHUR NR. (1972). Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukaemia. Cancer Res., 32, 1137-1142.
45. MILLOT JM, RASOANAIVO TDW, MORJANI H AND MANFAIT M. (1989). Role of aclacinomycin-A-doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells. Br. J. Cancer. 60, 678-684.
46. MIMNAUGH EG, DUSRE L, ATWELL J AND MYERS CE (1989). Differential oxygen radical susceptibility of adriamycin-sensitive and -resistant MCF-7 human breast tumour cells. Cancer Res., 49, 8-15.
47. MORTENSEN SA. (1987). Aclarubicin: preclinical and clinical data suggesting less chronic cardiotoxicity compared with conventional anthracyclines. Eur. J. Haematol., 47, 21-31.
48. MUGGIA FM AND GREEN MD. (1991). New anthracycline antibiotics. Crit. Rev. Oncol. Hematol., 11, 43-64.
49. MULDER HS, DEKKER H, PINEDO HM AND LANKELMA J. (1995). The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. Biochem. Pharmacol., 50, 967-974.
50. OKI T, TAKEUCHI T, OKA S AND UMEZAWA H. (1981). New antibiotic aclacinomycin-A: experimental studies and correlations with clinical trials. Recent Results Cancer Res., 76, 21-40.
51. OKUYAMA T, MAEHARA Y, ENDO K, BABA H, ADACHI Y, KUWANO M AND SUGIMACHI K. (1994). Expression of glutathione S-transferase-pi and sensitivity of human gastric-cancer cells to cisplatin. Cancer, 74, 1230-1236.
52. PAUL C, LILIEMARK J, TIDEFELDT U, GARTHON G AND PETERSON C. (1989). Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther. Drug Monit., 11, 140-148.
53. PEDERSEN-BJERGAARD J, BRINCKER H, ELLEGAARD J, DRIVSHOLM A, FREUND L, JENSEN KB, JENSEN MK AND NISSEN NL (1984). Aclarubicin in the treatment of nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabin: a phase II trial. Cancer Treat. Rep., 68, 1233-1238.
54. SCAMBIA G, PANICI PB, CONTU G, DE VINCENZO R, FERRANDINA G, ISOLA G, MACCIO A AND MANCUSO S. (1994). Mechanisms and modulation of resistance to anthracyclines (review). Int. J. Oncol., 4, 951-959.
55. SCOTT CA, WESTMACOTT D, BROADHURST MJ, THOMAS GJ AND HALL MJ. (1986). Absence of cross-resistance to adriamycin in human and murine cell cultures. Br. J. Cancer, 53, 595-600.
56. SEHESTED M, SKOVSGAARD T, VANDUERS B AND WINTHER-NIELSON H. (1987). Increase in nonspecific adsorptive endocytosis in anthracycline- and vinca alkaloid-resistant Ehrlich ascites in tumor cell lines. J. Natl Cancer Inst., 78, 171-177.
57. SKOVSGAARD T. (1987). Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin. Eur. J. Haematol., 38 (suppl. 47), 7-14.
58. SONNEVELD P, MARIE JP, LOKHORST HM, NOOTER K AND SCHOESTER M. (1994). Clinical modulation of multidrug resistance in VAD-refractory multiple myeloma: studies with cyclosporin and SDZ PSC 833. Anti-Cancer Drugs, 5 (suppl. 1), 72.
59. STREETER DG, JOHL JS, GORDON GR AND PETERS JH (1986). Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P833 cells. Cancer Chemother. Pharmacol., 16, 247-252.
60. TARASIUK J, FRÉZARD F, GARNIER-SUILLEROT A AND GATTEGNO L. (1989). Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration. Biochim. Biophys. Acta, 1013, 109-117.
61. TEETER LD, HSU H-C, CURLEY SA, TONG MJ AND KUO MT. (1993). Expression of multidrug resistance (P-glycoprotein) MDR1 and MDR2 genes in human hepatocellular carcinomas and liver metastases of cooling tumors. Int. J. Oncol., 2, 73-80.
62. WEAVER JL, PINE AS, ASZALOS A, SHOENLEIN PV, CURRIER SJ, PADMANABHAN R AND GOTTESMAN MM. (1991). Laser scanning and confocal microscopy of daunorubicin, doxorubicin, and rhodamine 123 in multidrug-resistant cells. Exp. Cell. Res., 196, 323-329.
63. WHEELER CS AND KESSEL D. (1980). Influx of anthracyclines by murine leukemia cells as a function of drug lipophilicity and membrane fluidity. Pharmacologist. 22, 291.
64. YUEN AR AND SIKIC BI. (1994). Multidrug resistance in lymphomas. J. Clin. Oncol., 12, 2453-2459.
65. ZENEBERGH A, BAURAIN R AND TROUET A. (1982). Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin. Cancer Chemother. Pharmacol., 8, 243-249.